Cambridge, Massachusetts, United States The main office of represented VC is situated in the Cambridge. The company was established in North America in United States.
For fund there is no match between the location of its establishment and the land of its numerous investments - France. Among the various public portfolio startups of the fund, we may underline InFlectis BioScience, Mitoconix Bio The fund has no exact preference in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Biopharma, Life Science. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Remiges Ventures, startups are often financed by Vesalius Biocapital Partners, VC Fonds Technologie Berlin, Lumira Ventures. The meaningful sponsors for the fund in investment in the same round are Vesalius Biocapital Partners, VC Fonds Technologie Berlin, SICAR. In the next rounds fund is usually obtained by Vesalius Biocapital Partners, VC Fonds Technologie Berlin, SICAR.
The fund is constantly included in less than 2 deals per year. The real fund results show that this VC is 63 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Related Funds
| Fund Name | Location |
| Abanumay Family Group | - |
| Ascolta Ventures | California, San Francisco, United States |
| Boston Scientific | Marlborough, Massachusetts, United States |
| CELAD | France, Midi-Pyrenees, Toulouse |
| Circadian Ventures | Atlanta, Georgia, United States |
| Cognizant | New Jersey, Teaneck, United States |
| Fawry | Al Qahirah, Cairo, Egypt |
| Flavin, Blake & Co. | - |
| GE Information Services | - |
| Havoc | California, San Francisco, United States |
| Hiventures Investment Fund | Budapest, Hungary |
| PG Ventures | Colorado, Denver, United States |
| Pinnacle Systems | California, Mountain View, United States |
| Red Bear Angels | New York, New York, United States |
| TheClubDeal | Belgium, Brussels-Capital, Uccle |
| Wellspring Capital Management | New York, New York, United States |
| Xueqiu Ziben | China, Hubei, Wuhan |
| Zhongguo Jiankang Chanye Touzi Jijin | Beijing, Beijing, China |
| Zhonghai Jiangyin (Beijing) Investment Management | Beijing, China, Haidian |
| Zhongze | China, Fujian, Hunan |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Cyrano Therapeutics | $9M | 16 Jan 2024 | Washington, District of Columbia, United States | ||
Restore Vision | $5M | 15 Dec 2023 | Chiyoda, Japan | ||
Restore Vision | $11M | 05 Jun 2023 | Chiyoda, Japan | ||
Kupando | $15M | 26 Sep 2022 | - | ||
Immunis | $10M | 03 Aug 2022 | Irvine, California, United States | ||
LUCA Science | $35M | 06 Jun 2022 | Chiyoda, Japan | ||
Restore Vision | $2M | 03 Feb 2022 | Chiyoda, Japan | ||
Viage Therapeutics | $10M | 06 Jan 2022 | San Francisco, California, United States | ||
Capacity Bio | 01 Jan 2022 | Palo Alto, California, United States |
– Glycomine, Inc. closed a $68m Series B financing.
– The proceeds of the financing will be used to advance Glycomine’s lead drug candidate, GLM101, through initial clinical trials in patients.
– GLM101 is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.
– The Series B financing includes $35m of new funds in addition to the $33m announced in August 2019.
– Today’s financing was led by new investors, Abingworth and Sanofi Ventures, and joined by RiverVest Venture Partners and Remiges Ventures.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Cyrano Therapeutics | $9M | 16 Jan 2024 | Washington, District of Columbia, United States | ||
Restore Vision | $5M | 15 Dec 2023 | Chiyoda, Japan | ||
Restore Vision | $11M | 05 Jun 2023 | Chiyoda, Japan | ||
Kupando | $15M | 26 Sep 2022 | - | ||
Immunis | $10M | 03 Aug 2022 | Irvine, California, United States | ||
LUCA Science | $35M | 06 Jun 2022 | Chiyoda, Japan | ||
Restore Vision | $2M | 03 Feb 2022 | Chiyoda, Japan | ||
Viage Therapeutics | $10M | 06 Jan 2022 | San Francisco, California, United States | ||
Capacity Bio | 01 Jan 2022 | Palo Alto, California, United States |
